BioLife Solutions SciSafe Division Secures $2.7 Million Cold Chain and Storage Contract for COVID-19 Vaccines

BioLife Solutions SciSafe Division Secures $2.7 Million Cold Chain and Storage Contract for COVID-19 Vaccines

BOTHELL, Wash., Oct. 14, 2020 /PRNewswire/ — BioLife Solutions, Inc. (NASDAQ: BLFS) (“BioLife” or the “Company”), a leading developer and supplier of a portfolio of class-defining bioproduction tools and services for cell and gene therapies, today announced its recently acquired SciSafe division has been awarded a two year contract from a large pharmaceutical company for cold chain management and storage of COVID-19 vaccines. The contract value is approximately $2.7 million.

Mike Rice, BioLife CEO, commented, “Garrie Richardson, former SciSafe CEO and now General Manager, Biologic Storage Services at BioLife, has built a great business and it’s clear SciSafe’s scalable and high quality operations are driving interest from leading  pharma companies. We are actively engaged in presenting SciSafe services to our marquee cell and gene therapy customers.”

Management estimates that SciSafe will contribute approximately $9 million in incremental revenue in 2021.

About SciSafe

Founded in 2010, SciSafe offers dedicated pharmaceutical and biological specimen storage in its four fully cGMP-compliant state-of-the-art sample management facilities. SciSafe has built flourishing relationships with a marquee list of the world’s leading and most admired organizations. Clients have repeatedly chosen to store their most valued and irreplaceable biological samples because they trust SciSafe to care for them as if they were their own. SciSafe values and respects its long-term client relationships. With over 60 years combined experience specifically in life sciences, SciSafe personnel fully appreciate the vital requirements of all areas of specimen storage and cold chain management. For more information, please visit www.scisafe.com.

More:  BioLife Solutions Announces Fourth Quarter and Full Year 2019 Financial Results

About BioLife Solutions

BioLife Solutions is a leading supplier of a portfolio of class-defining cell and gene therapy bioproduction tools and services. Our tools portfolio includes our proprietary CryoStor® freeze media and HypoThermosol® shipping and storage media, ThawSTAR® family of automated, water-free thawing products, evo® cold chain management system, and Custom Biogenic Systems high capacity storage freezers. Services include SciSafe biologic and pharmaceutical materials storage. For more information, please visit www.biolifesolutions.com, and follow BioLife on Twitter.

Cautions Regarding Forward Looking Statements

Except for historical information contained herein, this press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, but are not limited to, statements concerning the expected financial performance of the company following the completion of its acquisition of SciSafe, the expected synergies between the company and SciSafe, the company’s ability to realize all or any of the anticipated benefits associated with the acquisition of SciSafe, the company’s ability to implement its business strategy and anticipated business and operations, including following the acquisition of SciSafe, the potential utility of and market for the company’s and SciSafe’s products and services, guidance for financial results for 2020 and 2021, including regarding SciSafe’s revenue, and potential revenue growth and market expansion, including with consideration to our acquisition of SciSafe. All statements other than statements of historical fact are statements that could be deemed forward-looking statements. These statements are based on management’s current expectations and beliefs and are subject to a number of risks, uncertainties and assumptions that could cause actual results to differ materially from those described in the forward-looking statements, including among other things, uncertainty regarding unexpected costs, charges or expenses resulting from the company’s acquisition of SciSafe or the 2019 acquisitions, charges or expenses resulting from the acquisition of SciSafe; market adoption of the company’s products (including the company’s recently acquired products) or SciSafe’s products; the ability of the SciSafe acquisition to be accretive on the company’s financial results; the ability of the company to implement its business strategy; uncertainty regarding third-party market projections; market volatility; competition; litigation; the impact of the COVID-19 pandemic; and those other factors described in our risk factors set forth in our filings with the Securities and Exchange Commission from time to time, including our Annual Report on Form 10-K, Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. We undertake no obligation to update the forward-looking statements contained herein or to reflect events or circumstances occurring after the date hereof, other than as may be required by applicable law.

More:  BioLife Solutions Announces Third Quarter 2020 Financial Results

SOURCE BioLife Solutions, Inc.


Print Friendly

More from: | Category: Medical Device Company News